#United States #New York #The Gross Law Firm #AbbVie #Cerevel Therapeutics

Important Notice for Cerevel Therapeutics Shareholders

Shareholders of Cerevel Therapeutics Holdings, Inc. (traded as ABBV) are being urged to make contact with The Gross Law Firm before June 3, 2025. This is a crucial timeframe during which investors should explore their legal options and rights related to the recent developments surrounding the company and its stock offerings.

Overview of the Situation

The Gross Law Firm, a nationally recognized entity specializing in class action lawsuits, has issued an advisory to all shareholders who purchased shares of Cerevel Therapeutics during a specified class period. This period runs from October 11, 2023 through August 1, 2024. The law firm is particularly interested in connecting with investors who sold or disposed of their shares during this time or those who held shares as of the January 8, 2024 record date, which was critical for voting on the merger with AbbVie Inc.

Key Allegations

The lawsuit arises from allegations that the secondary stock offering conducted by Cerevel on October 16, 2023, did not fully disclose material facts concerning AbbVie's intention to acquire the company at a significantly higher price than the offering price of $22.81 per share. It has been claimed that these omissions artificially deflated the stock price until the merger was formally announced. The investment firm Bain Capital, which orchestrated the acquisition of shares during this period, is alleged to have done so while possessing significant insider information regarding AbbVie’s intentions.

Interestingly, on December 6, 2023, it became public knowledge that AbbVie agreed to acquire Cerevel for $45 per share, allowing Bain Capital to profit immensely from shares bought at the previously lower price.

Registration and Deadlines

For shareholders looking to protect their interests, the time is of the essence. Interested parties are advised to register their details through The Gross Law Firm’s contact avenues. The registration allows investors to participate in portfolio monitoring, keeping them updated on the progress and developments of the class action suit. The cut-off for seeking a lead plaintiff role is also highlighted as June 3, 2025.

Importance of Legal Representation

The Gross Law Firm emphasizes the importance of legal representation for investors who may have suffered losses due to misleading statements and omissions from the company. They stress that participating in this class action does not incur any fees unless recovery is achieved, making it a risk-free avenue for shareholders.

Contact Information

For inquiries and further information, shareholders can connect with the firm directly:

• - Phone: (646) 453-8903
• - Email: [email protected]
• - Office Location: 15 West 38th Street, 12th Floor, New York, NY 10018.

In today’s fast-paced economy, knowledge is power, and all Cerevel Therapeutics shareholders are encouraged to take proactive steps to understand their rights and explore potential remedies available through legal avenues. Don't delay in reaching out before the June 3, 2025 deadline to ensure your voice is heard.